Results 31 to 40 of about 4,657 (129)

Initial real‐world experience with lecanemab prescribing patterns in Japan: The Longevity Improvement & Fair Evidence (LIFE) Study

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Introduction Lecanemab, an anti‐amyloid‐beta antibody, is approved in over 40 countries. Patient demographic data exist for the US but are limited elsewhere. This study examined early real‐world lecanemab use in Japan.
Kengo Kawaguchi, Megumi Maeda, Futoshi Oda, Yasuharu Nakashima, Haruhisa Fukuda   +4 more
doaj   +1 more source

Probable lecanemab-associated pontine hemorrhage following cardiovascular intervention: Clinical implications for lecanemab use

Journal of Alzheimer's Disease Reports
We report a 76-year-old patient with mild cognitive impairment and APOE ε3/ε3 genotype who developed a rare pontine hemorrhage following treatment with lecanemab, an anti-amyloid-β monoclonal antibody for Alzheimer's disease.
Siwei Chen, Yongan Sun, Lanqiu Yao, Qing Peng   +3 more
doaj   +1 more source

Neurodegenerative Diseases: Epidemiology, Risk Factors, Classification, Pathophysiology, Clinical Features, Diagnosis, and Therapeutic Strategies

MedComm, Volume 7, Issue 11, November 2026.
Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He, Jingjing Zeng, Guoqing Wang, Yuxin Li, Feng Zhang   +4 more
wiley   +1 more source

Recognising Mild Cognitive Impairment and Early Alzheimer's Disease in General and Psychiatric Practice: Clinical Clues and Appropriate Referral

Psychogeriatrics, Volume 26, Issue 6, November 2026.
ABSTRACT Early cognitive decline may become evident through changes in daily activities or behaviour before it is apparent in a brief consultation. This selective narrative review supports case‐finding and appropriate referral in general and psychiatric practice.
Kengo Shimoda
wiley   +1 more source

Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Lecanemab is a monoclonal antibody targeting amyloid plaques that has been approved for the treatment of early symptomatic Alzheimer's disease.
Bethany C. Curd, Camilla Zubrick, Christine J. Cliatt Brown, Michelle Keown Sorweid, Sarah B. Dehoney, Yoshimi Anzai, Satoshi Minoshima, Anna L. Parks, Nicholas A. Frost   +8 more
doaj   +1 more source

Neuron‐Targeted Exosomal Delivery of siRNA Against RIPK3 Slows Neurodegenerative Progression in Alzheimer's Disease

Advanced Science, Volume 13, Issue 55, 5 October 2026.
Engineered exosomal siRNA delivery platform enables systemic, neuron‐targeted RNA transport across the blood–brain barrier. Surface functionalization with rabies virus glycoprotein‐derived peptide facilitates receptor‐mediated transcytosis, achieving efficient cytosolic delivery and robust gene silencing. Targeting RIPK3 suppresses necroptosis, reduces
Chi Zhang, Jiaqi Zhang, Yuzhi Wang, Yaodong Wang, Peng Lin, Yanling Wang, Zixuan Tang, Jintai Yu, Qin Zhou, Feiyun Cui   +9 more
wiley   +1 more source

Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease

Alzheimer’s Research & Therapy
Background Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (Aβ)-directed antibody indicated for the treatment of early AD ...
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer   +13 more
doaj   +1 more source

Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system

Frontiers in Pharmacology
ObjectiveStudies on anti-Aβ drugs for the treatment of Alzheimer’s disease (AD) have garnered significant attention; however, their safety still requires further research and monitoring. Although recent studies have analyzed the adverse drug events (ADEs)
Lingti Kong, Lingti Kong, Lingti Kong, Xiaohu Yang, Xiaohu Yang, Jian Xu, Jian Xu   +6 more
doaj   +1 more source

Perspectives from Alzheimer's Disease Research Centers site directors on the early steps and the lasting impact

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract Since the groundbreaking work of Alois Alzheimer in the early 1900s, Alzheimer's disease research has evolved immensely, most notably with the establishment of the Alzheimer's Disease Research Centers (ADRC). Fueled by the vision and funding of the National Institute on Aging (NIA), ADRCs have created a legacy through their work standardizing ...
John H. Growdon, John C. Morris, Ronald C. Petersen, Mary Sano, Lon S. Schneider   +4 more
wiley   +1 more source

Lecanemab real-world treatment outcomes from cohort study in early Alzheimer's disease

Journal of Alzheimer's Disease Reports
Lecanemab has demonstrated amyloid reduction and slowed clinical decline in early Alzheimer's disease trials. Herein, we report retrospective case series results on lecanemab treatment in our clinic. Overall, 61 individuals were included.
Alyanna Ferrer, Justin Moon
doaj   +1 more source